- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 27.10. | Zenas' lead autoimmune drug prompts 95% reduction in new brain lesions in phase 2 MS study | ||
| 27.10. | BridgeBio aces phase 3 rare disease test, clearing path to FDA | ||
| 27.10. | MapLight goes public via $250M IPO to fund Cobenfy competitor | ||
| 27.10. | GSK pens $357M pact with French biotech for preclinical prostate cancer ADC | ||
| 24.10. | Eli Lilly buys cash-strapped Adverum for its phase 3-stage eye disease gene therapy | ||
| 24.10. | Biogen beefs up immunology pipeline with $1B deal for Vanqua's preclinical C5aR1 antagonist | ||
| 24.10. | Sanofi drops RSV vaccine for toddlers after phase 3 trial heads for failure | ||
| 23.10. | Regeneron does 180 on 2seventy lymphoma CAR-T, halting study and nixing further development | ||
| 23.10. | Ventyx's CV drug reduces cardio risk biomarker by nearly 80% in 1st week of phase 2 study | ||
| 23.10. | Roche axes 4 Chugai solid tumor assets in early-phase clearout | ||
| 22.10. | Moderna scraps congenital virus program after vaccine shows little protective effect in phase 3 | ||
| 22.10. | Arcturus' stock halves after mRNA therapy fails to evoke efficacy in cystic fibrosis trial | ||
| 22.10. | Alector halves staff after GSK-partnered antibody flops phase 3 dementia trial | ||
| 22.10. | Sanofi's $1.7B rare disease bet beats CSL's Zemaira in phase 2 face-off | ||
| 22.10. | Ipsen writes check worth up to €1B to acquire next-gen cancer biotech | ||
| 22.10. | Takeda pays Innovent $1.2B upfront for rights to 2 cancer candidates | ||
| 22.10. | Terns mothballs obesity program after phase 2 data fall short | ||
| 21.10. | 'We need to pick a lane': Lilly oncology president weighs in on FDA cancer drug policies | ||
| 21.10. | GSK unveils positive pivotal data for Spero's once-rejected oral antibiotic | ||
| 21.10. | Neuphoria nixes social anxiety program and starts strategic review after phase 3 flop | ||
| 21.10. | Galapagos to wind down cell therapy unit, threatening 365 jobs and 5 facilities | ||
| 20.10. | US private equity shows signs of recovery, positions year to end 'on a high note': PitchBook | ||
| 20.10. | BioNTech fades out further work with cancer vaccine prospect in late-stage melanoma setting | ||
| 20.10. | How to invest in America? Vaccinate: BIO rolls out awareness campaign amid rising misinformation | ||
| 20.10. | ESMO: Daiichi, Merck power ovarian cancer ADC toward pivotal test after passing phase 2 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .